Repositioning VU-0365114 as a novel microtubule-destabilizing agent for treating cancer and overcoming drug resistance

Pharmacology, Toxicology and Pharmaceutical Science

• Malignant Neoplasm 100%
• Drug Resistance 100%
• Anticarcinogen 50%
• Adverse Event 50%
• Drug Development 50%
• Nude Mouse 50%
• Tumor Growth 50%
• Multiple Drug Resistance 50%
• P-Glycoprotein 50%
• Colorectal Tumor 50%
• Tubulin 50%
• Colorectal Cancer 50%
• Muscarinic Receptor 50%
• Positive Allosteric Modulator 50%
• Repurposing 50%
• Neoplasm 50%
• Drug Repositioning 50%

Biochemistry, Genetics and Molecular Biology

• Antineoplastic Activity 100%
• Drug Resistance 100%
• Gene Expression 50%
• Nude Mouse 50%
• Cancer Cell 50%
• Anticancer 50%
• Tubulin 50%
• Multidrug Resistance 50%
• Kinome 50%
• Muscarinic Acetylcholine Receptor M5 50%
• Tumor Progression 50%
• P-Glycoprotein 50%

Medicine and Dentistry

• Malignant Neoplasm 100%
• Microtubule 100%
• Drug Resistance 100%
• Antineoplastic Activity 40%
• In Vitro 20%
• Cancer Therapy 20%
• Cancer Cell 20%
• Gene Expression 20%
• Adverse Event 20%
• Anticarcinogen 20%
• Tumor Progression 20%
• ABC Transporter Subfamily B 20%
• Tubulin 20%
• Colorectal Tumor 20%
• Colorectal Cancer 20%
• Multidrug Resistance 20%
• Tumor Xenograft 20%
• Muscarinic Acetylcholine Receptor 20%
• Allosteric Modulator 20%
• Drug Repositioning 20%